For example, pembrolizumab, which targets PD-1, is approved by the Food and Drug Administration (FDA) for treating advanced NSCLC patients without mutations in EGFR or ALK and with high PD-L1 expression [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.